Celltrion USA has signed an agreement with the pharmacy benefit manager Express Scripts that will place the company’s subcutaneous formulation of infliximab on the Express Scripts National Preferred Formulary. While Express Scripts handles health plans for more than 100 million Americans, the PBM gave the biosimilar Preferred Brand Access that will reach 21.9 million insured customers.
Marketed under the name Zymfentra, the drug is the first US Food and Drug Administration approved